Oscotec Inc.

Translating science into medicine
Sign Up

Sign Up

Sign In
PRESS

NEWSROOM

Notice Press Releases Publications IR Materials
Home NEWSROOM Press Releases
TDefault
✔ Go Website with Viewer Search Write
List of Articles
Date Website Media Pipeline
2019-01-28 Genosco gears up for IPO THE INVESTOR Genosco
2018-11-23 Oscotec`s acute leukemia treatment wins orphan drug status from FDA KBR (; Korea Biomedical Review) SKI-G-801
2018-11-05 Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech BusinessKorea Lazertinib
2018-06-11 Yuhan ups investment in biotechs for immuno-oncology drug push THE INVESTOR Yuhan/Lazertinib
2018-06-03 "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC" Businesswire Lazertinib
2018-05-16 Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018 Businesswire Lazertinib
2018-03-14 More than half of Korean biopharma firms view R&D investments as assets. The Korea Herald Industry
2017-12-11 Oscotec shares rebound on launch of US clinical trial KBR (; Korea Biomedical Review) SKI-G-801
2016-08-23 INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs Scrip (Informa Pharma Intelligence) Oscotec
2016-01-19 Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money Scrip (Informa Pharma Intelligence) SYK-O-703
2014-04-03 G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. PubMed SKI-G-801
2007-02-19 Profiles of Four New Stock-Billionaires MBN Oscotec
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.